Your browser is no longer supported. Please, upgrade your browser.
PRAH PRA Health Sciences, Inc. monthly Stock Chart
PRA Health Sciences, Inc.
Index- P/E28.61 EPS (ttm)3.67 Insider Own0.20% Shs Outstand62.93M Perf Week-2.84%
Market Cap6.81B Forward P/E18.84 EPS next Y5.57 Insider Trans-2.75% Shs Float- Perf Month8.07%
Income239.60M PEG3.93 EPS next Q1.09 Inst Own99.70% Short Float- Perf Quarter16.63%
Sales3.13B P/S2.18 EPS this Y55.70% Inst Trans-0.62% Short Ratio3.28 Perf Half Y-4.79%
Book/sh17.60 P/B5.96 EPS next Y29.06% ROA6.90% Target Price106.77 Perf Year9.34%
Cash/sh2.32 P/C45.17 EPS next 5Y7.27% ROE22.60% 52W Range58.67 - 113.32 Perf YTD-5.62%
Dividend- P/FCF37.99 EPS past 5Y45.00% ROI12.70% 52W High-7.43% Beta1.06
Dividend %- Quick Ratio0.90 Sales past 5Y16.00% Gross Margin28.00% 52W Low78.80% ATR3.12
Employees17500 Current Ratio0.90 Sales Q/Q8.50% Oper. Margin11.50% RSI (14)54.19 Volatility3.97% 2.78%
OptionableYes Debt/Eq1.17 EPS Q/Q-4.20% Profit Margin7.80% Rel Volume0.75 Prev Close101.38
ShortableYes LT Debt/Eq1.15 EarningsAug 06 AMC Payout0.00% Avg Volume352.47K Price104.90
Recom2.40 SMA200.18% SMA504.10% SMA2006.50% Volume271,573 Change3.47%
Aug-10-20Downgrade BofA Securities Buy → Underperform $110 → $100
May-01-20Downgrade William Blair Outperform → Mkt Perform
Apr-13-20Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-20Downgrade Goldman Buy → Neutral $130 → $120
Jan-07-20Initiated Citigroup Neutral $120
Nov-14-19Upgrade Wolfe Research Peer Perform → Outperform
Sep-19-19Initiated Goldman Buy $126
Sep-13-19Upgrade KeyBanc Capital Markets Sector Weight → Overweight
May-03-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Oct-09-18Initiated UBS Neutral
Oct-04-18Initiated Evercore ISI In-line
Jan-24-18Downgrade Mizuho Buy → Neutral $86
Dec-11-17Initiated Barclays Overweight $94
Dec-01-17Reiterated Mizuho Buy $82 → $87
Aug-17-17Initiated Raymond James Outperform $89
Jun-26-17Initiated BofA/Merrill Buy $89
Feb-27-17Upgrade Avondale Mkt Underperform → Mkt Perform
Feb-06-17Upgrade Credit Suisse Neutral → Outperform
Sep-06-16Downgrade UBS Buy → Neutral $50 → $55
Jun-21-16Initiated First Analysis Sec Equal-Weight $47
Aug-12-20 03:51PM  
Aug-11-20 08:10AM  
Aug-06-20 04:55PM  
Jul-30-20 12:34PM  
Jul-28-20 05:17PM  
Jul-13-20 01:34PM  
Jul-09-20 10:00AM  
Jul-02-20 01:20PM  
Jun-18-20 08:05AM  
Jun-15-20 09:24AM  
Jun-12-20 08:05AM  
Jun-08-20 02:40AM  
May-30-20 11:31AM  
May-18-20 12:22PM  
May-04-20 09:29AM  
May-01-20 07:01PM  
Apr-30-20 07:05PM  
Apr-29-20 12:10PM  
Apr-23-20 12:32PM  
Apr-20-20 08:28AM  
Apr-13-20 09:42AM  
Apr-08-20 04:05PM  
Mar-26-20 02:38PM  
Mar-24-20 04:05PM  
Mar-23-20 10:12AM  
Mar-22-20 04:46PM  
Mar-21-20 11:30AM  
Mar-20-20 05:08PM  
Mar-17-20 09:00AM  
Mar-11-20 04:02PM  
Mar-10-20 06:02AM  
Feb-25-20 05:40PM  
Feb-24-20 02:59PM  
Feb-20-20 05:45PM  
Feb-13-20 12:31PM  
Feb-05-20 12:34PM  
Feb-03-20 04:01PM  
Jan-22-20 05:16PM  
Jan-08-20 01:53PM  
Jan-07-20 08:45AM  
Dec-26-19 10:15AM  
Dec-11-19 11:04AM  
Dec-02-19 09:09PM  
Nov-21-19 02:31PM  
Nov-20-19 09:08AM  
Nov-05-19 10:35AM  
Nov-01-19 07:58AM  
Oct-30-19 07:25PM  
Oct-27-19 11:02AM  
Oct-23-19 10:34AM  
Oct-17-19 09:43AM  
Oct-09-19 04:05PM  
Oct-08-19 01:48PM  
Sep-19-19 10:25AM  
Sep-18-19 08:00AM  
Sep-09-19 03:14PM  
Sep-04-19 08:48AM  
Sep-03-19 05:59PM  
Aug-19-19 12:00PM  
Aug-05-19 02:37PM  
Aug-01-19 03:39PM  
Jul-31-19 08:45PM  
Jul-30-19 11:45AM  
Jul-25-19 08:58AM  
Jul-24-19 10:32AM  
Jul-11-19 10:08AM  
Jul-09-19 04:15PM  
Jul-02-19 08:42AM  
Jun-20-19 09:24PM  
Jun-17-19 09:11AM  
May-31-19 09:31AM  
May-14-19 07:00AM  
May-13-19 06:28PM  
May-09-19 12:00PM  
May-03-19 04:34PM  
May-01-19 06:45PM  
Apr-24-19 12:14PM  
Apr-22-19 11:33AM  
Apr-21-19 09:06PM  
Apr-18-19 10:30AM  
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bonello Michael J.EVP & CFOApr 27Sale87.973,672323,02623,328Apr 28 04:08 PM
KKR Fund Holdings L.P.10% OwnerSep 06Sale97.416,666,684649,401,68829,300Sep 10 05:09 PM
KKR PRA Investors L.P.10% OwnerSep 06Sale97.416,666,684649,401,68829,300Sep 10 04:51 PM